Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) - Total Liabilities
Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has total liabilities worth CN¥207.05 Million CNY (≈ $30.30 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688505 operating cash flow to assess how effectively this company generates cash.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Total Liabilities Trend (2005–2024)
This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 688505 financial resilience to evaluate the company's liquid asset resilience ratio.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vamos Locação de Caminhões Máquinas e Equipamentos S.A
SA:VAMO3
|
Brazil | R$19.84 Billion |
|
Shandong Weida Machinery Co Ltd
SHE:002026
|
China | CN¥931.92 Million |
|
Vanjee Technology Co Ltd
SHE:300552
|
China | CN¥958.76 Million |
|
Ability Enterprise Co Ltd
TW:2374
|
Taiwan | NT$3.57 Billion |
|
Abacus Life Inc.
NASDAQ:ABL
|
USA | $479.34 Million |
|
Sido Muncul PT
JK:SIDO
|
Indonesia | Rp561.44 Billion |
|
Jaya Real Property Tbk
JK:JRPT
|
Indonesia | Rp4.20 Trillion |
|
Shanghai Holystar Information Technology Co. Ltd. A
SHG:688330
|
China | CN¥337.44 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Shanghai Fudan-Zhangjiang Bio-Pharmaceut.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2024)
The table below shows the annual total liabilities of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥281.23 Million ≈ $41.15 Million |
-45.72% |
| 2023-12-31 | CN¥518.12 Million ≈ $75.82 Million |
-28.34% |
| 2022-12-31 | CN¥722.99 Million ≈ $105.80 Million |
+22.21% |
| 2021-12-31 | CN¥591.58 Million ≈ $86.57 Million |
+20.19% |
| 2020-12-31 | CN¥492.21 Million ≈ $72.03 Million |
-22.08% |
| 2019-12-31 | CN¥631.68 Million ≈ $92.43 Million |
+35.53% |
| 2018-12-31 | CN¥466.08 Million ≈ $68.20 Million |
+84.47% |
| 2017-12-31 | CN¥252.65 Million ≈ $36.97 Million |
+2.00% |
| 2016-12-31 | CN¥247.70 Million ≈ $36.25 Million |
-2.64% |
| 2015-12-31 | CN¥254.43 Million ≈ $37.23 Million |
+71.84% |
| 2014-12-31 | CN¥148.06 Million ≈ $21.67 Million |
-19.22% |
| 2013-12-31 | CN¥183.29 Million ≈ $26.82 Million |
-33.87% |
| 2012-12-31 | CN¥277.18 Million ≈ $40.56 Million |
+75.64% |
| 2011-12-31 | CN¥157.81 Million ≈ $23.09 Million |
+16.51% |
| 2010-12-31 | CN¥135.45 Million ≈ $19.82 Million |
+3.82% |
| 2009-12-31 | CN¥130.46 Million ≈ $19.09 Million |
+58.00% |
| 2008-12-31 | CN¥82.57 Million ≈ $12.08 Million |
+39.15% |
| 2007-12-31 | CN¥59.34 Million ≈ $8.68 Million |
+36.97% |
| 2006-12-31 | CN¥43.32 Million ≈ $6.34 Million |
+125.88% |
| 2005-12-31 | CN¥19.18 Million ≈ $2.81 Million |
-- |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more